Pear Therapeutics today announced the publication of positive results from real-world data of its reSET-O prescription digital therapeutic.
Boston-based Pear Therapeutics evaluated its FDA-authorized reSET-O PDT in the treatment of opioid use disorder (OUD) on patients treated for 24 weeks, with real-world evidence demonstrating that the treatment is associated with improved outcomes, high levels of treatment retention and fewer hospital encounters compared to 12 weeks of the treatment.
Get the full story at our sister site, Drug Delivery Business News.